Head-to-Head Survey: bioAffinity Technologies (BIAF) vs. its peers

bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is one of 39 publicly traded companies in the “Commercial Physical Research” industry, but how does it compare to its competitors? We will compare bioAffinity Technologies to related companies based on the strength of analyst recommendations, profitability, risk, earnings, dividends, valuation and institutional ownership.

Insider and institutional ownership

1.6% of bioAffinity Technologies shares are held by institutional investors. By comparison, 52.6% of the shares of all “Commercial Physical Research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. By comparison, 16.7% of the shares of all “Commercial Physical Research” companies are owned by insiders. Strong institutional ownership is an indication that major money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares the revenue, earnings per share and valuation of bioAffinity Technologies and those of its competitors.

BioAffinity Technologies’ competitors have higher revenues and earnings than bioAffinity Technologies. bioAffinity Technologies trades at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its sector.

Risk and volatility

bioAffinity Technologies has a beta of 3.93, indicating that its stock price is 293% more volatile than the S&P 500. In comparison, bioAffinity Technologies’ peers have a beta of 6.02, indicating that their average stock price is 502% more volatile than the S&P 500. .

Analyst recommendations

This is an overview of recent ratings for bioAffinity Technologies and its competitors, as reported by MarketBeat.

As a group, “Commercial Physical Research” companies have a potential advantage of 12.78%. Given the higher odds for bioAffinity Technologies’ competitors, analysts clearly believe that bioAffinity Technologies has less favorable growth aspects than its peers.

Profitability

This table compares the net margins, return on equity, and return on assets of bioAffinity Technologies and those of competitors.

Resume

bioAffinity Technologies’ competitors defeated bioAffinity Technologies on 9 out of 10 factors compared.

About bioAffinity technologies

(Get a free report)

bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and targeted cancer therapies. The company offers CyPath Long, a diagnostic test, for the early detection of lung cancer. It is also investigating targeted therapies to treat lung cancer and other lung diseases at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Receive daily news and reviews for bioAffinity Technologies – Enter your email address below to receive a daily digest of the latest news and analyst ratings for bioAffinity Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.